Imaging Striatal Dopamine Release Using a Non-Genetically Encoded Near-Infrared Fluorescent Catecholamine Nanosensor

Abraham G. Beyene¹, Kristen Delevich², Jackson Travis Del Bonis-O’Donnell¹, David J. Piekarski¹, Wan Chen Lin², A. Wren Thomas³, Sarah J. Yang¹, Polina Kosillo⁴, Darwin Yang¹, Linda Wilbrecht²,³, Markita P. Landry¹,³,⁵,⁶*

¹ Department of Chemical and Biomolecular Engineering, University of California, Berkeley, Berkeley, CA, USA
² Department of Psychology, University of California, Berkeley, Berkeley, CA, USA
³ Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA
⁴ Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA
⁵ California Institute for Quantitative Biosciences (QB3), Berkeley, CA, USA
⁶ Chan-Zuckerberg Biohub, San Francisco, CA, USA

*e-mail: landry@berkeley.edu

Abstract

Neuromodulation plays a critical role in brain function in both health and disease. New optical tools are needed that can image neuromodulation with high spatial and temporal resolution, which will add an important new dimension of information to neuroscience research. Here, we demonstrate the use of a catecholamine nanosensor with fluorescent emission in the 1000-1300 nm near-infrared window to measure dopamine transmission in ex vivo brain slices. These near-infrared catecholamine nanosensors (nIRCats) represent a broader class of nanosensors that can be synthesized from non-covalent conjugation of single wall carbon nanotubes (SWNT) with single strand oligonucleotides. We show that nIRCats can be used to detect catecholamine efflux in brain tissue driven by both electrical stimulation or optogenetic stimulation. Spatial analysis of electrically evoked signals revealed dynamic regions of interest approximately 2 microns in size in which transients scaled with simulation intensity and lasted 5-10 seconds. Optogenetic stimulation of dopaminergic terminals, but not glutamatergic terminals, produced similar nIRCat transients. Bath application of autoreceptor antagonist sulpiride increased nIRCat signal, while bath application of receptor agonist quinpirole decreased nIRCat signal. Furthermore, bath application of nomifensine prolonged nIRCat fluorescence signal, consistent with reuptake blockade of dopamine. These nanosensors may be advantageous for future use because they i) do not require virus delivery, gene delivery, or protein expression, ii) their near-infrared fluorescence facilitates imaging in optically scattering brain tissue and is compatible for use in conjunction with other optical neuroscience tool sets, and iii) the broad availability of unique near-infrared colors have the potential for simultaneous detection of multiple neurochemical signals and in the presence of pharmacological agents. Together, these data suggest nIRCats and other nanosensors of this class can serve as versatile new optical tools to report dynamics of extracellular neuromodulation in the brain.
Main

The catecholamines dopamine and norepinephrine are neuromodulators known to play an important role in learning and attention and are implicated in multiple brain disorders.\(^1\)–\(^5\) Dopamine, in particular, is thought to play a critical role in learning\(^6\), motivation\(^7,8\), and motor control\(^9\), where aberrations in dopamine neurotransmission are implicated in a wide range of neurological and psychiatric disorders including Parkinson’s disease\(^10\), schizophrenia\(^11\), and addiction.\(^12\)

Neuromodulatory neurotransmission is thought to occur on a broader spatial scale than classic neurotransmission, whereby classic neurotransmission is mediated by synaptic release of glutamate and \(\gamma\)-aminobutyric acid (GABA) in the central nervous system. In synaptic glutamatergic and GABAergic neurotransmission, neurotransmitter concentrations briefly rise in the synaptic cleft to mediate local communication between the pre- and postsynaptic neurons through the rapid activation of ligand-gated ion channels.\(^13\) In contrast, neuromodulators (catecholamines, neuropeptides) may diffuse more broadly beyond the synaptic cleft and act via extrasynaptically-expressed metabotropic receptors.\(^14\)–\(^19\) Thus, modulatory neurotransmitter activity extends beyond single synaptic partners and enables small numbers of neurons to modulate the activity of broader networks.\(^20\) The larger spatial scale and often absence of direct change in ionic flux across cell membranes makes quantification of neuromodulation a challenge.

Ideally, to understand how neuromodulation sculpts brain activity, we need to develop tools that can optically report modulatory neurotransmitter concentrations in the brain extracellular space (ECS) in a manner that is compatible with pharmacology and other available tools to image neural structure and activity. This goal motivates our effort to design an optical sensor that can report extracellular catecholamine dynamics with high spatial and temporal fidelity within a unique near-infrared spectral profile. In this work, we describe the design, characterization, and implementation of a nanoscale near-infrared (nIR) non-genetically encoded fluorescent reporter that allows precise measurement of catecholamine dynamics in brain tissue. This technology makes use of a single wall carbon nanotube (SWNT) non-covalently functionalized with single strand (GT)\(_6\) oligonucleotides to form the near-infrared catecholamine nanosensor (nIRCat). nIRCats respond to dopamine with \(\Delta F/F\) of up to 24-fold in the fluorescence emission window of 1000-1300 nm\(^48\), a wavelength range that has shown utility for non-invasive through-skull imaging in mice.\(^42\) First, we show \textit{in vitro} data characterizing the specificity of the nanosensor for catecholamines dopamine and norepinephrine, and demonstrate the nanosensor’s insensitivity to GABA, glutamate, and acetylcholine. Second, we use \textit{ex vivo} brain slices containing the dorsal striatum to demonstrate that nIRCats exhibit a fractional change in fluorescence that has the dynamic range and signal-to-noise ratio to report dopamine efflux in response to brief electrical or optogenetic stimulation of dopaminergic terminals. Optogenetic stimulation of this preparation is also used to demonstrate the selectivity of the nIRCat nanosensor response to dopaminergic over glutamatergic terminal stimulation. Consistent with the role of presynaptic dopamine autoreceptors in regulating dopamine release, bath application of dopamine autoreceptor antagonist sulpiride increased nIRCat signal, while bath application of receptor agonist quinpirole decreased nIRCat signal.
Finally, the presence of a dopamine reuptake inhibitor, nomifensine, yields a prolonged nIRCat fluorescent signal indicating that the sensors report a change in the time course of dopamine diffusion and reuptake in striatal brain tissue. These data indicate that nIRCats provide a unique tool to interrogate the release, diffusion, and reuptake of neuromodulators in intact neural tissue and in the presence of pharmacological agents.

A Near-Infrared Dopamine and Norepinephrine Nanosensor

We report near-infrared fluorescent catecholamine nanosensors (nIRCats) that enable imaging of extrasynaptic catecholamines and their release and re-uptake dynamics in the ECS of brain tissue. Using a previously established nanosensor generation platform\textsuperscript{21,22}, synthetic bio-mimetic polymers were pinned onto the surface of intrinsically near-infrared fluorescent single-wall carbon nanotubes (SWNT). The resulting non-covalent nanometer-scale conjugate produced the catecholamine-selective nIRCat. In \textit{in vitro} solution phase experiments (Methods), nIRCats exhibited a maximal change in fluorescence ($\Delta F/F$) of up to 24 (Figure 1b, 1c) with a dynamic range of 4 orders of magnitude, reporting detectable fluorescence changes from 10 nM to 100 µM dopamine concentration (Figure S1). nIRCats can also serve as norepinephrine sensors with a maximal response of $\Delta F/F=35$ and a similar dynamic range (Figure S1). We showed that nIRCats are insensitive to GABA, glutamate, and acetylcholine (Figure 1c), and can measure fluctuations in dopamine concentration in the presence of ascorbic acid, which is present in cerebrospinal fluid (Figure S1). Single-molecule imaging revealed that the nanosensors were reversible upon exposure to repeated perfusions of 10 µM dopamine (Figure S2), an important feature for measuring neuromodulator kinetics. In previous work, we performed stochastic simulations that suggest nIRCats have sufficient sensitivity to detect physiologically relevant fluctuations in dopamine concentration in brain tissue arising from the activity of a single dopaminergic terminal, which can briefly exceed concentrations of 1 µM from the release site in a distance-dependent manner.\textsuperscript{23}
Figure 1. Synthesis and testing of near-infrared catecholamine nanosensors (nIRCats). (a) Schematic of optical catecholamine reporters, nIRCats. Pristine SWNT are functionalized with (GT)$_6$ oligonucleotides to generate turn-on optical reporters for dopamine (DA) and norepinephrine (NE). (b) Fluorescence spectra of nIRCats before (black) and after (red) addition of 10 µM of dopamine in an in vitro preparation in phosphate buffered saline (without tissue). Multiple emission peaks correspond to unique SWNT chiralities contained within the multi-chirality mixture. (c) Nanosensor optical response to 100 µM dopamine (DA), norepinephrine (NE), glutamate (GLU), γ-aminobutyric acid (GABA), and acetylcholine (ACH) (data from in vitro testing). Black bars represent averages from n=3 independent measurements and error bars are calculated as standard deviations of the n=3 measurements.

Imaging of electrical stimulation-evoked dopamine release in acute striatal brain slices

To determine the efficacy of nIRCats for imaging dopamine in brain tissue, we used brain slices from the dorsal striatum of the mouse. The dorsal striatum is densely innervated by dopaminergic projections from the substantia nigra pars compacta (SNc) but lacks significant innervation from cells that release norepinephrine (NE), therefore we leveraged nIRCats capacity to serve as a dopamine sensor in this striatal brain region. The majority of neurons within the striatum are GABAergic medium spiny neurons (MSNs) with a minority fraction of interneuron populations that include GABAergic and cholinergic interneurons. Glutamatergic inputs from the cortex and thalamus are the major drivers of MSN activity and dopaminergic terminals in close proximity to these inputs are thought to play an important role in modulating the activity of MSNs and plasticity at striatal synapses. Due to the composition of local axons, intrastriatal
electrical stimulation is predicted to drive release of GABA, glutamate, acetylcholine, and dopamine, but negligible amounts of other catecholamines like norepinephrine.

Coronal mouse brain slices were prepared as described previously.\textsuperscript{27} Slices were subsequently incubated with 2 mg/L nIRCats for 15 minutes to enable sensors to diffuse into the brain tissue (Figure 2a). Slices were subsequently rinsed to remove excess nIRCats and incubated in standard artificial cerebrospinal fluid (ACSF) for another 15 minutes before imaging. This method, modified from Godin \textit{et al.}\textsuperscript{28} who demonstrated that SWNT localize in the brain ECS of acute slices, enabled even and widespread labeling of the coronal slice, including the dorsal striatum (Figure 2c). Imaging of nIRCat fluorescence modulation in dorsal striatum was accomplished with a custom-built visible and near-infrared microscope to enable concurrent imaging of both visible (400 nm – 750 nm) and near-infrared (750 nm – 1700 nm) wavelengths on the same detector (Figure 2b). Briefly, a 785 nm laser for excitation of nIRCats and mercury bulb for generating brightfield images were directed onto the back focal plane of an epifluorescence upright microscope, and imaging channels were selected using a sliding mirror. Serially, either brightfield or near-infrared images were collected on a Ninox Vis-SWIR 640 broadband camera (Raptor Photonics) with appropriate dichroic filters (Methods) and a 60X water dipping objective (Nikon) providing an imaging field of 178 μm by 142 μm, containing hundreds of dopaminergic terminals.
To investigate striatal neuromodulator release with temporal control of tissue stimulation, we used a bipolar stimulating electrode to evoke terminal release within the dorsomedial striatum (stimulus protocol: 3 millisecond wide single square pulses, over 5 biological replicates). We found a single pulse could elicit a nIRCat signal transient, and that increasing the strength of the stimulus led to larger evoked changes in nIRCat $\Delta F/F$ signal, $(\Delta F/F)_{max}$ 0.1 mA = 0.0465 ± 0.025; 0.3 mA = 0.122 ± 0.026; and 0.5 mA = 0.2 ± 0.033; mean ± s. d., n=5 for all measurements, p=0.0078 between 0.1 mA vs. 0.3 mA, p=0.0076 between 0.3 mA vs. 0.5 mA) (Figure 3b).

To further test if evoked nIRCat signals tracked striatal dopamine release and reuptake kinetics, we investigated the effect of nomifensine, a dopamine reuptake inhibitor that slows the clearance of dopamine from the ECS by competitively binding to dopamine...
transporters (DATs). Addition of 10 µM nomifensine to the bath yielded nIRC signal with higher peak fluorescence modulation \((\Delta F/F)_{\text{max}} = 0.108 \pm 0.029 \text{ vs. } 0.189 \pm 0.023; \text{ mean } \pm \text{ s. d., } n=3, p=0.0178\) and a prolonged fluorescent signal compared to signals obtained in ACSF from the same field of view (decay time constant, \(\tau = 2.43 \pm 0.24 \text{ s vs. } 10.95 \pm 1.15 \text{ s; mean } \pm \text{ s. d., } n=3, p=0.0002\)) (Figure 3a top vs. bottom row, Figure 3c).

Figure 3. Imaging and spatiotemporal analysis of dopamine release evoked by electrical stimulation in acute striatal slices. (a) Nanosensor \(\Delta F/F\) imaging of the same acute brain slice field of view upon electrical stimulation by 0.3 mA in standard ACSF (top row) and in ACSF plus 10 µM nomifensine (bottom, +Nomifensine). Three still frames are presented from each movie. “Pre” is a representative frame before electrical stimulation is applied, “Stim” represents frame corresponding to peak \(\Delta F/F\) following stimulation, and “Post” is a representative frame after nIRCat fluorescence has returned to baseline. Scale bars = 10 µm. (b) Nanosensor fluorescence modulation scales with single pulse electrical stimulation amplitudes. Field of view mean traces and standard deviation bands are presented for three stimulation amplitudes of 0.1 mA, 0.3 mA, and 0.5 mA (n=5) (c) Time traces of \(\Delta F/F\) for 0.3 mA single pulse stimulation in standard ACSF (red) and in ACSF plus 10 µM nomifensine (purple, +NOMF). Mean traces with standard deviation bands are presented (n=3). (d) A single frame from a time series of imaging in the dorsomedial striatum showing the...
To identify nIRCats fluorescence change hotspots (i.e., regions of high ∆F/F), we analyzed our video-rate acquisitions using a custom-built program that accounted for background fluorescence and identified regions with fluctuations in fluorescence intensity in the post-stimulation epoch (see Methods for details). We defined nIRCats ∆F/F hotspots as regions of interest (ROIs) based on a per-pixel stack projection of maximal ∆F/F in the imaging time series. The ROIs identified were found to vary in size from 1 µm to 15 µm (Figure 3d, 3e). We found that ∆F/F hotspots do not necessarily correspond to high nIRCats labeling of the brain tissue, suggesting that the hotspot is a consequence of variation in dopamine release not nanosensor loading in the tissue (Figure 3d, Figure S3). Using data from single pulse electrical stimulation experiments, the program identified ROIs whose size distribution was observed to exhibit a log-normal distribution with median ROI size of 2 µm (Figure 3e). Repeat stimulations with the same stimulation amplitude in fields of view of the dorsomedial striatum across biological replicates generated similar size distributions (Figure 3f). Closer examination of several larger ROIs (> 5µm) suggested these may be comprised of smaller hot-spots in close proximity (Figure 3g).

For further examination of the temporal resolution of nIRCats, we compared the temporal profile of evoked transients measured with nIRCats to transients measured with fast scan cyclic voltammetry (FSCV). FSCV is a technique that has been widely utilized to measure catecholamine dynamics both in vivo and in vitro in the striatum and other brain areas. FSCV and nIRCats experiments were conducted on separate experimental rigs with the same solutions, temperature settings, electrodes, and stimulation parameters. Evoked transients measured with FSCV and nIRCats fluorescence emission showed comparable temporal profiles in the rising phase (latency to peak: FSCV = 0.25 ± 0.0 s vs. nIRCats = 0.40 ± 0.18 s; mean ± s. d., n=4 fields of view from 2 biological replicates, p=0.2291). Meanwhile, nIRCats signals exhibited a wider diversity of decay kinetics (τ: FSCV = 0.51 ± 0.08 s vs. nIRCats = 2.43 ± 0.24 s; mean ± s. d. n=4 fields of view from 2 biological replicates, p=0.0002). A subset of ROIs exhibited decay time constants that overlapped with those of FSCV signals (Figure 3h, 3i).
We next evaluated the ability of nIRCats to detect dopamine in the presence of dopamine receptor (DR) drugs. In *in vitro* solution phase experiments (without biological tissue), we found that nIRCat fluorescence intensity was not modulated by 1 µM quantities of DRD2 antagonists sulpiride and haloperidol, the DRD2 agonist quinpirole, or the DRD1 antagonist SCH-23390 (Figure 4a). Furthermore, dopamine-induced nIRCat fluorescence signals were not altered in the presence of dopamine receptor drugs (Figure 4a). In *ex vivo* brain slices (dorsal striatum), application of quinpirole (1 µM) abolished nIRCat
fluorescent transients in response to single electrical pulse stimulation which was rescued following 15-minute drug wash-out (Figure 4b, 4c). Conversely, application of sulpiride (1 µM) significantly increased nIRCat ΔF/F (Figure 4d, 4e). The effects of quinpirole and sulpiride were reproducible in n=3 biological replicates (Figure 4f). Importantly, the effects of D2 receptor pharmacology on nIRCat fluorescence modulation by dopamine were absent in vitro and only present in brain tissue. In brain tissue, presynaptic dopamine receptors play a critical role in regulating dopamine release, and our results are consistent with powerful inhibition of dopamine efflux by the DRD2 agonist quinpirole and facilitation of dopamine efflux by the DRD2 antagonist sulpiride.

**Imaging of optogenetically-evoked dopamine release in acute striatal brain slices**

To further confirm striatal nIRCat nanosensor signals were indeed reporting dopamine release, we compared channelrhodopsin (ChR2) stimulation of cortical glutamatergic and nigrostriatal dopaminergic terminals in the dorsal striatum. Acute striatal brain slices were prepared from mice virally transfected to express the light sensitive cation channel ChR2 in either dopaminergic terminals (targeted by viral injection in the midbrain in DAT-cre mice; ChR2-DA) (Figure 5c) or glutamatergic terminals of the striatum (targeted by viral injection in the frontal cortices, ChR2-GLU) (Figure 5a). Upon optical stimulation of ChR2-DA terminals with a 473 nm laser (5 pulses at 25 Hz, 1 mW/mm²) in the dorsal striatum, we observed significant fluorescence modulation of nIRCat signal (Figure 5d). When optogenetic stimulation instead targeted glutamatergic terminals, we could observe excitatory postsynaptic currents (EPSCs) in an MSN neuron, but fluorescent nIRCat signals did not rise above baseline fluctuation (Figure 5b).

Returning to ChR2-DA stimulation, we next varied the number of stimulation pulses (5 ms pulse duration, 25 Hz, 1 mW/mm²) and observed scaling in nIRCat ΔF/F amplitude from 1 pulse to 10 pulses (p=0.005), and trend level differences between 1 pulse and 5 pulses (p=0.0645), and 5 pulses and 10 pulses (p=0.086) (Figure 5e). When we varied the pulse frequency while holding the number of pulses constant at 5, we observed scaling with significant differences detectable between 1 Hz and 10 Hz (p=0.036). The amplitude difference between 10 Hz and 25 Hz did not reach significance (p=0.179) (Figure 5f). In single pulse experiments in which we varied pulse width, nIRCat fluorescence responses scaled with pulse duration. This was significant comparing 2 ms to 5 ms (p=0.002) but the scaling from 5 ms to 10 ms did not rise to significance (p=0.055) (Figure 5g).

Finally with ChR2-DA stimulation experiments, we tested use of dopaminergic pharmacological agents. Bath application of quinpirole (1 µM) powerfully suppressed nIRCat fluorescence (p<0.0001), and this change reversed in washout (Figure 5h). Nomifensine (10 µM) enhanced nIRCat signal decay time, consistent with the predicted slowing of dopamine clearance from the ECS (Figure S4).
Figure 5. Optogenetic release of dopamine imaged by nIRCat. (a) Schematic of ChR2 expression in cortical glutamatergic terminals of the dorsal striatum. (b) No nIRCat fluorescence modulation was observed after stimulation of glutamate terminals. Inset: glutamate release was confirmed by excitatory postsynaptic current on medium spiny neuron. (c) Schematic of ChR2 expression in nigrostriatal dopaminergic terminals of the dorsal striatum. (d) Stimulation of dopaminergic terminals resulted in nIRCat fluorescence modulation. Stimulation protocol in (b) and (d) was 5 pulses at 25 Hz and power flux of 1 mW/mm² and each pulse had a duration of 5ms. (e) nIRCat ∆F/F in response to increasing number of pulses delivered at 25 Hz, 5 ms pulse duration. (f) nIRCat ∆F/F in response to increasing pulse frequency (1, 10, 25 Hz) of 5 pulses. Each pulse had a duration of 5 ms. (g) nIRCat ∆F/F in response to single pulses of 2 ms, 5 ms and 10 ms duration. (h) Bath application of 1 µM of quinpirole suppresses dopamine release and results in depressed nIRCat ∆F/F. Drug wash-out rescues dopamine release and nIRCat ∆F/F.

Conclusion

To capture spatial information of neuromodulator kinetics and to integrate our understanding of neuromodulation with other measures of brain activity, there is need for new optical tools to measure the extracellular dynamics of neuromodulator release and reuptake. Here, we demonstrated the feasibility of using of a non-genetically encoded fluorescent sensor, nIRCat, which enables optical detection of catecholamine release and reuptake with sub-second temporal and with micrometer spatial resolution. We used electrical and optogenetic methods in ex vivo brain slices to demonstrate that nIRCat fluorescent signals can successfully report differences in evoked dopamine release and pharmacologically induced changes in dopamine reuptake kinetics in striatal tissue.

Here, we focused nIRCat imaging experiments within the dorsal striatum, a region that receives dense dopaminergic innervation and negligible norepinephrine innervation. Therefore, while nIRCat are not selective for dopamine over norepinephrine, they effectively function as a dopamine sensor within the context of the striatum. Given that striatal dopamine regulates fundamental processes including motor function, motivation and learning, nIRCat represent an important addition to the neuroscience investigative toolkit.

While other tools are emerging to optically report dopamine fluctuations via cell-surface engineered proteins, nIRCats are likely to fulfill a niche amongst currently available methods for detecting dopamine neurotransmission due to their unique near-infrared fluorescence, compatibility with pharmacology, and because they do not rely on genetic delivery and expression. In addition, the functionality of nIRCats is not hindered by the presence of dopamine receptor ligands, in contrast to receptor-based fluorescent sensors which cannot report endogenous dopamine in the presence of ligands to the engineered receptor. nIRCat decay profiles exhibit a wider range than that observed from FSCV data, and included a significant number of ROIs that showed seconds-long time constants. These results may capture the unique spatial property of nIRCats: unlike FSCV probes which sample catecholamine concentration at a single point in space, each distributed nIRCat molecule can act as a probe within the ECS and therefore yield a “higher resolution” picture of catecholamine dynamics. Future experiments will investigate how the heterogeneity of nIRCat signals (amplitude and kinetics) relates to structural and functional properties at
dopamine terminals and within the ECS. We predict that new optical tools for measuring dopamine dynamics with high spatial resolution will be enable new sights into the regulation of dopamine release and reuptake.34–36

In the future, we see potential for expansion of a larger family of SWNT based near-infrared nanosensors (nIRNS) similar to nIRCats for multiple neurochemical imaging applications. Several lines of evidence illustrate their future potential. First, nIRNS are easily functionalized with a wide range of synthetic molecular recognition moieties, affording fine control of their surface functional elements and their interactions with the local chemical environment.37–39 SWNT fluorescence can be finely tuned to monochromatic emission in the near-infrared II (1000–1700 nm) window by controlling the SWNT chirality.40 This chirality-dependent fluorescence in the near-infrared II window provides further avenues for designing color-specific responses to multiple molecular analytes simultaneously, thereby affording synthesis of ratiometric and multiplexed analyte imaging platforms, as we have shown previously.41 Second, SWNT-based nanosensors rely on near-infrared fluorescence, which greatly reduces the impact of tissue scattering in the emission window and therefore may enable through-cranium imaging.42 nIRNS are compatible with multi-photon imaging with 1600 nm excitation43 and as such could permit nanoscale imaging of intact neuronal structures as has been shown with visible wavelength-emitting fluorophores.44 Third, nIRNS have robust photostability allowing for use in long-term imaging experiments.45 Fourth, because nIRNS are not genetically-encoded, they could enable use in species where gene delivery and protein expression is too difficult, time consuming, or undesirable. Finally, nanosecond-scale binding kinetics and the nanoscale dimensions of nIRNS48, are likely to enable generation of nanosensors with improved temporal and spatial resolution. In sum, nIRCats are versatile catecholamine probes amenable to multiplexing with existing tools for concurrent investigation of dopaminergic neuromodulation with other core mechanisms of brain function.

Methods

Nanosensor synthesis

(GT)_6 oligonucleotides were purchased from Integrated DNA Technologies (IDT, Standard Desalting). HiPCo SWNT were purchased from NanoIntegris (Batch # HR27-104). (GT)_6-SWNT colloidal suspension (nIRCat) was prepared by mixing 1 mg of (GT)_6 and 1 mg of SWNT in 1 mL of a 100 mM NaCl solution. The solution was bath sonicated (Branson Ultrasonic 1800) for 10 minutes and probe-tip sonicated for 10 minutes at 5 W power (Cole Parmer Ultrasonic Processor, 3 mm tip diameter) in an ice-bath. The sonicated solution was incubated at room temperature for 30 minutes. The product was subsequently centrifuged at 16,000 g (Eppendorf 5418) for 90 minutes to remove unsuspended SWNT bundles and amorphous carbon, and the supernatant was recovered for characterization and use. Each nanosensor suspension was stored at 4°C until use.

Nanosensor characterization
To characterize nIRCats post-synthesis, the full visible and near-infrared absorption spectrum was taken for each nanosensor batch (UV-VIS-NIR spectrophotometer, Shimadzu UV-3600 Plus) or UV-VIS (ThermoFisher Scientific Genesys 20). SWNT concentrations of as-made nanosensor batches were determined using absorbance at 632 nm (UV-VIS) with an extinction coefficient of $\varepsilon = 0.036 \text{ (mg/L)}^{-1} \text{ cm}^{-1}$. Full spectrum absorbance measurements were made with UV-VIS-NIR after dilution to 5 mg/L SWNT concentration in 100 mM NaCl. For fluorescence spectroscopy, each sensor batch was diluted to a working concentration of 5 mg/L in 100 mM NaCl, and aliquots of 198 µL were placed in each well of a 96-well plate (Corning). Fluorescence measurements were obtained with a 20 X objective on an inverted Zeiss microscope (Axio Observer.D1) coupled to a Princeton Instruments spectrograph (SCT 320) and liquid nitrogen cooled Princeton Instruments InGaAs linear array detector (PyLoN-IR). A 721nm laser (OptoEngine LLC) was used as the excitation light source for all characterization experiments.

Neurotransmitter and dopamine receptor drug screening

For neurotransmitter response screens, we collected the near-infrared fluorescence spectrum from 198 µL aliquots of nanosensor (5 mg/L SWNT concentration) before and after addition of 2 µL of 10 mM solutions of each analyte neurotransmitter (for a 100 µM final analyte concentration in each well of a 96-well plate). All neurotransmitter analytes were purchased from Sigma-Aldrich. Neurotransmitter analytes were incubated for 5 minutes before taking post-analyte fluorescence measurements. Responses were calculated for the integrated fluorescence count as $\Delta F/F_0 = (F-F_0)/F_0$, where $F_0$ is total fluorescence before analyte addition and $F$ is total fluorescence after analyte addition or for peak fluorescence change corresponding to the (9,4) SWNT chirality (~1128 nm center wavelength). All measurements were made in triplicate. Reported results are mean and standard deviations of the triplicate measurements. All nIRCat nanosensor batches were tested for catecholamine responses prior to use for tissue catecholamine imaging. Dopamine receptor drugs were purchased from Tocris (quinpirole and sulpiride), abcam (SCH 23390), and Sigma-Aldrich (haloperidol). nIRCat fluorescence modulation to dopamine receptor drugs were measured after addition of 1 µM drug quantities (final concentration in well) in each well. Post-drug fluorescence spectra were taken after 5-minute drug incubation. To measure nIRCat response to dopamine in the presence of drugs, dopamine aliquots were added to each drug-incubated well to obtain 100 µM dopamine, and post-dopamine fluorescence spectra were taken after an additional 5-minute incubation period.

Nanosensor reversibility testing

A #1.5 glass coverslip was functionalized with (3-Aminopropyl) triethoxysilane (APTES, Sigma Aldrich) by soaking in 10% APTES in ethanol for 5 min. The coverslip was then rinsed with DI water and left to dry. The coverslip was then fixed onto an ibidi sticky-Slide VI 0.4 forming 6 microfluidic channels. First, 100 µL of PBS was pipetted through a channel. Next, the channel was filled 50 µL of a 5 mg/L solution of nIRCats and left to incubate at room temperature for 5 min. The channel was rinsed using three 50 µL PBS
washes, keeping the channel filled with solution at all times. The surface immobilized nIRCats in PBS were imaged on an epifluorescence microscope with 721 nm excitation and a Ninox VIS-SWIR 640 camera (Raptor). One end of the flow channel was connected to a syringe pump (Harvard Apparatus) using Luer lock fittings. Prior to the start of image acquisition, the opposite flow reservoir was filled with PBS and the pump was set to refill mode at a volumetric flow rate of 40 μL min\(^{-1}\). Once the liquid in the reservoir was depleted, 40 μL of 10 μM dopamine in PBS was added. The process was repeated using alternating additions of 80 μL of PBS washes and 40 μL of dopamine solution.

**Acute slice preparation and nanosensor labeling**

Mice were C57 Bl/6 strain, 60 days old, and both male and female mice were used. Mice were group housed after weaning at P21 and kept with nesting material on a 12:12 light cycle. All animal procedures were approved by the UC Berkeley Animal Care and Use Committee (ACUC). Acute brain slices were prepared using established protocols. Briefly, mice were deeply anesthetized via intraperitoneal injection of ketamine/xylazine cocktail and transcardial perfusion was performed using ice-cold cutting buffer (119 mM NaCl, 26.2 mM NaHCO\(_3\), 2.5 mM KCl, 1mM NaH\(_2\)PO\(_4\), 3.5 mM MgCl\(_2\), 10 mM Glucose, 0 mM CaCl\(_2\)), after which the brain was rapidly extracted. The cerebellum and other connective tissues were trimmed using a razor blade and the brain was mounted onto the cutting stage of a vibratome (Leica VT 1200S). Coronal slices (300 μm in thickness) including the dorsal striatum were prepared. Slices were incubated at 37°C for 60 minutes in oxygen saturated ACSF (119 mM NaCl, 26.2 mM NaHCO\(_3\), 2.5 mM KCl, 1mM NaH\(_2\)PO\(_4\), 1.3 mM MgCl\(_2\), 10 mM Glucose, 2 mM CaCl\(_2\)) before use. Slices were then transferred to room temperature for 30 minutes before starting imaging experiments and were maintained at room temperature for the remainder of experimentation.

For nanosensor labeling, slices were transferred into a small volume brain slice incubation chamber (Scientific Systems Design, Inc., AutoMate Scientific) and kept under oxygen saturated ACSF (total 5 mL volume). 100 μL of 100 mg/L nIRCat nanosensor was added to the 5mL volume and the slice was incubated in this solution for 15 minutes. The slice was subsequently recovered and rinsed in oxygen saturated ACSF to wash off nIRCats that did not localize into the brain tissue. The rinsing step was performed by transferring the slice through 3 wells of a 24 well plate (5 seconds in each well) followed by transfer to the recording chamber with ACSF perfusion for a 15-minute equilibration period before starting the imaging experimentation. All imaging experiments were performed at 32°C.

**Acute slice preparation for FSCV recording**

Acute slices were prepared as described previously. Extracellular dopamine concentration evoked by local electrical stimulation was monitored with FSCV at carbon-fiber microelectrodes (CFMs) using Millar voltammeter. CFMs were ~ 7 μm in diameter encased in glass capillary pulled to form a seal with the fiber and cut to final tip length of 70-120 μm. The CFM was positioned ~100 μm below the tissue surface at a 45-degree angle. A triangular waveform was applied to the CFM scanning from -0.7 V to +1.3 V and back, against Ag/AgCl reference electrode at a rate of 800 V/s. Evoked dopamine transients
were sampled at 8 Hz, and data were acquired at 50 kHz using AxoScope 10.5 (Molecular Devices). Oxidation currents evoked by electrical stimulation were converted to dopamine concentration from post-experimental calibrations. Recorded FSCV signals were identified as dopamine by comparing oxidation (+0.6 V) and reduction (-0.2 V) potential peaks from experimental voltammograms with currents recorded during calibration with 2 µM dopamine dissolved in ACSF. For stimulation, a bipolar stimulation electrode (FHC CBAEC75) was positioned on top of the brain slice and approximately 100 µm away from the CFM. Following 30-minute slice equilibration in the recording chamber, dopamine release was evoked using a square pulse (0.3 mA pulse amplitude, 3 ms pulse duration) controlled by Isoflex stimulus isolator (A.M.P.I) and delivered out of phase with the voltammetric scans. Stimulation was repeated 3 times. To compare FSCV and nIRcat data, each signal was normalized against its peak value ([DA]_max or (ΔF/F)_max) and co-aligned at stimulation time. Latency to peak were computed as t_{peak} - t_{stim} where t_{peak} is the time at which peak signal is attained and t_{stim} is time of stimulation. Decay time constants (τ) were computed from model fits to a first order decay process.

Microscope construction and slice imaging

Ex vivo slice imaging was performed with a modified upright epifluorescent microscope (Olympus, Sutter Instruments) mounted onto a motorized stage. Nanosensor excitation was supplied by a 785 nm, CW, DPSS laser with adjustable output power to a maximum of 300 mW and a near TEM00, top hat beam profile (OptoEngine LLC). The beam was expanded using a Keplerian beam expander comprised of two plano-convex lenses (Thorlabs, f=25 mm, f=75 mm, AR coating B) to a final beam diameter of approximately 1 cm. The beam was passed through a custom fluorescence filter cube (excitation: 800 nm shortpass (FESH0800), dichroic: 900 longpass (DMLP990R), emission: 900 longpass (FELH0900), Thorlabs) to a 60X Apo objective (1.0 NA, 2.8 mm WD, water dipping, high NIR transmission, Nikon CFI Apo 60XW NIR). Emission photons collected from the sample were passed through the filter cube and were focused onto a two-dimensional InGaAs array detector (500-600 nm: 40% quantum efficiency (QE); 1000-1500 nm: >85% QE; Ninox 640, Raptor Photonics) and recorded using Micro-Manager Open Source Microscopy Software.46 Laser power was adjusted to maximize collected photons and fill the pixel bit depth on the detector but did not exceed 70 mW at the objective back focal plane. YFP fluorescence was imaged by switching the filter cube (FESH 0899 for excitation, FELH 0900 for emission, Thorlabs) and using a mercury-vapor lamp (Olympus) for excitation.

Electrical and optical stimulation-evoked dopamine imaging with near-infrared microscopy

For electrical stimulation experiments, a bipolar stimulation electrode was positioned in field of view within the dorsomedial striatum identified using a 4X objective (Olympus xFluor 4x/340). Using 60X objective, the stimulation electrode was brought into contact with top surface of the brain slice and an imaging field of view was chosen at a nominal distance of 150 µm from the stimulation electrode within the dorsomedial striatum. All stimulation experiments were recorded at video frame rates of 9 frames per second (nominal) and single pulse electrical stimulations were applied after 200 frames of baseline
were acquired. Each video acquisition lasted 600 frames. Stimulation amplitudes were staggered and each stimulation amplitude was repeated three times within a field of view. Slices were allowed to recover for 5 minutes between each stimulation with the excitation laser path shuttered. For optogenetic stimulation, a fiber-coupled 473 nm blue laser (OptoEngine LLC DPSS) was positioned in close proximity to the brain slice using a micromanipulator. Expression of ChR2 was confirmed via visible fluorescence imaging and an imaging field of view was chosen in dorsomedial striatum with robust expression level. Stimulation pulses (5 pulses, 5 ms duration per pulse, delivered at 25 Hz, 1 mW/mm²) were delivered after acquiring 200 baseline frames and the video acquisition lasted 600 frames at nominal 9 frames per second. Drugs were bath applied to the imaging chamber through ACSF perfusion. ACSF with 10 µM nomifensine or 1 µM of each DRD drug was used. When the effect of a drug needed to be evaluated, stimulation/imaging experiments were carried out with drug-free ACSF in an imaging field of view to collect drug-free data. ACSF was then switched to ACSF prepared with the drug of interest and applied for 10 minutes before stimulation/imaging experiments resumed.

**Viral transfection of mice for optogenetic stimulation**

Adult male and female mice (>P60) were used for all surgeries. Bilateral viral injections were performed using previously described procedures at the following stereotaxic coordinates: dorsomedial prefrontal cortex (dmPFC): 1.94 mm from Bregma, 0.34 mm lateral from midline, and 0.70 mm vertical from cortical surface; substantia nigra pars compacta (SNc): -3.08 mm from Bregma, 1.25 mm lateral from midline, and 4.0 mm vertical from cortical surface. For glutamatergic corticostriatal axon stimulation experiments, mice were injected with 0.5 µL of CAG-ChR2-EYFP virus bilaterally into dmPFC. For nigrostriatal dopaminergic axon stimulation experiments, DAT-Cre mice were injected with 0.5 µL DIO-ChR2-EYFP virus bilaterally. For all optogenetic experiments, we waited at least three weeks from viral injection to experimental stimulation to allow for sufficient ChR2 gene expression.

**Image processing and data analysis of nIRCat fluorescence response**

Raw movie files were processed using a custom-built MATLAB program (available for download: https://github.com/jtdbod/Nanosensor-Brain-Imaging). Briefly, for each raw movie stack (600 frames), a per pixel \( \frac{(F-F_0)}{F_0} \) was calculated using the average intensity for the first 5% of frames as F0. Regions of interest (ROIs) were identified by calculating a median filter convolution and then performing thresholding using Otsu’s method followed by a morphological dilation operation. \( \Delta F/F \) traces were then calculated for each generated ROI. ROI sizes were computed using the measured pixel area and approximating each as a circle to calculate an equivalent radius.

To compare responses across stimulation amplitudes and bath application of nomifensine, mean results were obtained as follows: First, all identified ROIs from a field of imaging were averaged. Mean traces were further averaged over different fields of view within the same slice and across slices (1-2 field of view per slice, 1-2 slices per animal) and then averaged over experimental animals. Decay time constants (\( \tau \)) were computed by fitting...
ΔF/F time traces to a first order decay process. Latency to peak were computed as \( t_{\text{peak}} - t_{\text{stim}} \) where \( t_{\text{peak}} \) is the time at which peak signal is attained and \( t_{\text{stim}} \) is time of stimulation. All statistical tests of significance (p-values) were computed and reported from unpaired, two-tailed t-test.

Acknowledgements

We acknowledge support of an NIH NIDA CEBRA award # R21DA044010 (to L.W.), a Burroughs Wellcome Fund Career Award at the Scientific Interface (CASII) (to M.P.L.), the Simons Foundation (to M.P.L.), a Stanley Fahn PDF Junior Faculty Grant with Award # PF-JFA-1760 (to M.P.L.), a Beckman Foundation Young Investigator Award (to M.P.L.), and a DARPA Young Investigator Award (to M.P.L.). M.P.L. is a Chan Zuckerberg Biohub investigator. A.G.B. is supported by an NSF Graduate Research Fellowship. The authors wish to thank Marla Feller, Helen Bateup, and David Schaffer for helpful discussions and comments on the manuscript and to Nicholas Ouassil for manuscript feedback.

Competing Interests

The authors declare no competing financial interests.

Data Availability Statement

All data as well as data processing software are available upon reasonable request to the corresponding author, and custom processing software is available on GitHub.

Supplementary Information

References

2. Solanto, M. V. Dopamine dysfunction in AD/HD: Integrating clinical and basic neuroscience research. in *Behavioural Brain Research* (2002). doi:10.1016/S0166-4328(01)00431-4


